

Net Performance of 96% in 30 months since start

The Medical Market Opportunity

Great momentum, high growth market driven by:

- Ageing population
- Increasing purchasing power of emerging markets
- Wish to maintain / improve quality of life
- Gene and cell therapy innovations becoming mature and coming to the market

Many new targets

Of the 700 public biotech companies in the EU + US, over 25% came to the market in the last 3 years. For many public biotech companies the real value inflection point is still to come. These companies often have emerged from a private equity setting and are at the forefront of innovation. Typically new medicine serve a global market and therefore have a potential for rapid growth / value creation.

High need for medical solutions in Alzheimer, Cancer, Diabetes, Infectious diseases, MS, Obesity, Parkinson and 7000 diseases without any treatment

- Focused and disciplined selection of around 18 companies from a total pool of 700
- Majority in Small / Mid cap in EU and US
- Where we expect substantial tangible value creation over 1-4 years, which should result in a share price increase of 2-5x
- Diversification, over disease areas, geographies and development phases
- Investing in management teams which can deliver
- Regular dialogue with management of an investment company
- High conviction investor, based on experience, knowledge, and network
- Managed buy and sell discipline based on fundamentals and pricing
- A team that puts its money where its mouth is (invested over €20 million)

Analysts

Lead analyst Maurits Brandt studied Biochemistry followed by a master in Life Science and Business. Analyst Paolo Del Bufalo obtained a Bachelor's degree in Chemistry at La Sapienza University of Rome after which he completed two Master tracks at Leiden University, one in Chemical Biology Research and one in Science Based Business.

4 Experienced fund advisors

The fund advisors all have a 30 year+ experience investing in and/or leading life sciences companies, all with a very successful track record. Two of the advisors, Bo Jesper Hansen and Gert Hoogland, are medical doctors who joined the life sciences industry early on in their medical career. Fred Oudshoorn has a background in pharmacy and is an investor in healthcare companies for many years. Michiel de Haan is a life sciences investor for over 25 years, in which period he was part of over 60 IPOs.

Portfolio Manager



Patrick Krol

Patrick (1963) joined Aescap at its start in 2005. He has been a board member with 8 (private + public) life sciences / biotech companies. Over the years Patrick built an extensive network in the life sciences industry. Parallel to having been an investor in private biotech companies, he has a good track record as a private investor in public biotech. His return over 2014 - 2017 was 170% outperforming the Nasdaq Biotech Index (NBI), by 75%. From 1995-2004 Patrick was a co-founder and managing director of Firm United Healthcare, a consultancy company with 25 FTE working with numerous international biotech and diagnostics companies, from small to large cap.

pkrol@aescap.com, +31 6 15 07 1415

Competitive terms

- Management Fee 1,5%
- Performance Fee 20% (no double dipping)
- Open-end
- Monthly entry / redemption
- Subscription fee 1%
- Redemption fee 0,2%
- 100% tax transparent
- Min. subscription amount € 500K
- Target net IRR of 20% per annum
- Investment team invested >€ 20M